Build engaged audiences through publishing by curation.
|Current selected tag: fees. Clear.|
Your new post is loading...
EVELYNE PIERRON's insight:
The European Medicines Agency has revised the rules on fees payable to the Agency. The revised rules, which come into force on 4 August 2013, provide for full waiver of fees for pharmacovigilance-related type-IA (immediate-notification) variations to the terms of marketing authorisations with the following scopes:
The European Commission has launched a three-month public consultation on a concept paper on the introduction of fees to be charged by the European Medicine Agency for new pharmacovigilance activities.
The deadline for comments on the paper is 15 September 2012.